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ABSTRACT
Objective: To identify the use of aspirin recommendations for primary prevention of cardiovascular disease, 
weighing its benefits and risks, according to the available literature. Methodology: This is an integrative 
review. Data collection took place in May 2014, accepted period of publications between 2009 and 2013 in 
English, Portuguese and Spanish. Results: 7 studies were selected, with excellent levels of recommendation. 
It was evident that the use of aspirin for primary prevention of cardiovascular disease should be based on 
a careful analysis of each case, assessing its benefits and risks. Conclusion: it is concluded that are required 
risk stratification tools to determine if it is recommend or not the use of aspirin. Although, there is a need for 
special training for the nursing staff to better monitor and treat these patients. Descriptors: Cardiovascular 
diseases. Aspirin. Prevention.
RESUMO
Objetivo: identificar as recomendações de uso da aspirina para a prevenção primária de doenças cardiovasculares, pesando seus benefícios 
e riscos, conforme a literatura disponível. Metodologia: trata-se de uma revisão integrativa, a coleta de dados aconteceu no mês de maio de 
2014, aceitaram-se publicações do período entre 2009 e 2013, em inglês, português e espanhol. Resultados: foram selecionados 07 estudos, 
com excelentes níveis de recomendação. Evidenciou-se que o uso da aspirina para a prevenção primária de doenças cardiovasculares 
deve ser baseado em uma análise criteriosa de cada caso, avaliando seus benefícios e riscos. Conclusão: conclui-se que são necessárias 
ferramentas de estratificação de riscos, para assim, recomendar ou não o uso da aspirina. Ainda que, há necessidade de capacitação 
especial à equipe de enfermagem para um melhor acompanhamento e tratamento destes pacientes. Descritores: Doenças cardiovasculares. 
Aspirina. Prevenção. 
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RESUMEN
Objetivo: Identificar el uso de las recomendaciones de la aspirina para la 
prevención primaria de la enfermedad cardiovascular, sopesando sus 
beneficios y riesgos, de acuerdo con la literatura disponible. Metodología: 
Este es un examen integrador, la recopilación de datos tuvo lugar en mayo 
de 2014, aceptada por periodo de publicaciones entre 2009 y 2013 en Inglés, 
Portugués y Español. Resultados: Se seleccionaron 07 estudios, con excelentes 
niveles de recomendación. Era evidente que el uso de la aspirina para la 
prevención primaria de las enfermedades cardiovasculares debe basarse en 
un análisis cuidadoso de cada caso, la evaluación de sus beneficios y riesgos. 
Conclusión: se concluye que se requieren herramientas de estratificación del 
riesgo, por lo tanto, recomendar o no el uso de la aspirina. Aunque, existe la 
necesidad de una formación especial para el personal de enfermería para un 
mejor control y tratamiento de estos pacientes. Descriptores: Enfermedades 
cardiovasculares. La aspirina. Prevención.
INTRODUCTION
The epidemiological transition is not so recent. In 
2004, more than 62% of the deaths occurred as a result of 
chronic noncommunicable diseases (CNCD), among them 
cardiovascular diseases (CVD). It is estimated that in 2020, 
these will be responsible for 25 million deaths worldwide 
every year.1 The CVD was also responsible for 1,155,489 
hospital admissions in 2007 and 69% of the Unified Health 
System expenditures (UHS).2
Because of this scenario, many studies focus on their 
prevention, some emphasize lifestyle modifications such as 
healthy diet, reduction of smoking, alcohol consumption, physical 
activity, and diseases such as hypertension, stress, dyslipidemias 
and diabetes,3-4 while others focus on pharmacological measures 
for primary and secondary prevention, that is, respectively, to 
avoid risks, determinants or causes of CVD; and promote early 
detection and return to a healthy status.5
Currently, the most commonly used drug for this 
purpose is aspirin, also known as ASA or acetylsalicylic 
acid. There are few studies in Brazil to identify and / or 
recommend the use of aspirin for this purpose, as well as 
to analyze the factors contributing to such use. However, 
outpatient and hospital studies have found use of around 
17.7% in the case of primary prevention and up to 98% in 
secondary prevention of CVD.4
Aspirin is one of the most widely used drugs in the world. 
Its origin dates back to 1897, when the German laboratory 
Bayer, through Henri Leroux and Raffaele Piria, respectively, 
French pharmacist and Italian chemist, conjugated acetate 
with salicylic acid, which has its active principle isolated in the 
crystalline form of Salix alba willow, forming Acetylsalicylic 
Acid (ASA). It is an oral administration drug, intestinal 
absorption, rapid distribution, with half-life of 4 hours, 
metabolized in the liver and excreted by the renal route.6
Only in 1939 was it approved by the Food and Drug 
Administration (FDA), being considered prototype and 
compared to all other non-steroidal anti-inflammatory 
drugs (NSAIDs). It is part of this group of drugs that act 
by inhibiting cyclooxygenase (COX) enzymes, causing a 
reduction in the synthesis of prostaglandins, which results in 
desirable and undesirable clinical-pharmacological events.7
It is known that all eicosanoids, among them 
prostaglandins, are synthesized by the COX pathways, which 
have two forms. While COX-1 acts in the regulation of normal 
cellular processes, COX-2 expresses constitutive function of 
tissues. Another difference between them is their structure, 
since COX-2 has a greater binding channel, which favors the 
development of selective COX-2 inhibitors, such as celecoxib, 
which inhibits COX-2 more than COX-1, being indicated 
similarly to other NSAIDs for pain relief and reduced risk 
of cardiovascular events, sometimes combined with aspirin. 
It is worth noting that aspirin is the only drug in the group 
capable of irreversibly inactivating COX; although it is rapidly 
deacetylated in the body, producing salicylate, which acts as 
an anti-inflammatory, antipyretic and analgesic.7-8
Its use in the prevention of cardiovascular diseases (CVD) 
is due to the fact that aspirin inhibits COX-1, preventing the 
release of thromboxanes A2 (TXA2) Responsible for platelet 
agglutination, thus reducing the risk of thrombus formation, 
coupled with the lack of antagonism to the effects of renal 
vasoconstrictors, usually caused by prostaglandins, but 
increasing the time of bleeding.7,9 
Considering the lack of studies in Brazil with this 
approach and focused at nursing professionals, the present 
study aimed to identify the recommendations of aspirin for 
the primary prevention of CVD, weighing its benefits and 
risks, according to available literature. To the extent that it 
is the responsible nurse, as a member of the health team, 
for the integral attention of the client, for the promotion of 
health and for the prevention of diseases, it becomes evident 
the necessity of appropriating knowledge such as the one 
produced in this study, thus facilitating the replacement of 
conducts previously accepted as safe, effective and accurate. 
METHOD
It is an integrative literature review in which the following 
steps were considered: formulation of the research question, 
definition of the inclusion criteria , search for studies, 
selection of studies and data collection, quality evaluation 
of studies, analysis and summary of the results.10 The 
research question of the present review was: which are the 
recommendations of aspirin use for the primary prevention 
of cardiovascular events, evaluating benefits and risks?
For this integrative literature review , a search was made in 
May 2014 at the Virtual Health Library (VHL) for evidence-
based reviews, systematic reviews, meta-analyzes, case series, 
descriptive studies, expert opinion and randomized clinical 
trials, non-randomized, experimental, non-experimental, 
and quasi-experimental studies, published between 2009 
and 2013 in English, Portuguese and Spanish, using the 
combined terms: cardiovascular diseases, aspirin and 
prevention, with the help of the Boolean operator AND.
After reading the abstracts and applying the inclusion and 
exclusion criteria, it was selected 7 studies in the VHL database; 
1250 were excluded because they did not meet the criteria 
selected for this study, 253 due to the reading of the titles and 
abstracts, 1 was repeated, 6 because they were subject to charges 
and 29 because they did not meet the objective of this review.
DOI: 10.9789/2175-5361.2017.v9i4.917-921
Evidence on the use of aspirin...
ISSN 2175-5361
Sousa KHJF; Fernandes SA; Costa GR; et al.
919J. res.: fundam. care. online 2017. out./nov. 9(4): 917-921
To extract data from included articles, a data collection instrument was used, organized according to the following items: 
publication title, journal title, authors, language, year of publication, objective, study design, sample, technique for collection 
and data analysis, description of the results, conclusions and level of evidence of the study.
In order to evaluate the quality of the studies and the strength of recommendation, a scale was used, for which the quality 
of the study is divided into 5 levels of evidence, where: 1: corresponds to the systematic review studies and meta-analyzes; 2: 
randomized controlled trials; 3: well-delineated studies, however, without randomization, cohort studies, time series and cases; 
4: well-delineated non-experimental studies, provided that these were performed in more than one research center or group; 
and 5: expert opinions, provided they are based on evidence and descriptive studies. As for the recommendation strength, 
according to the previous levels, it is classified in 3 degrees (strong: levels 1 and 2, moderate: level 3 and weak: levels 4 and 5).11 
Data analysis was performed in two stages. In the first stage, it was analyzed the data referring to the year of publication, 
indexing period, country of origin of the study, methodological approach and level and strength of evidence. The data were 
grouped and analyzed using mathematical operations of frequency distribution and percentage. In the next stage, the content 
of the studies was analyzed, observing the recommendations of the use of aspirin for the primary prevention of CVD. 
RESULTS AND DISCUSSION
The 7 studies selected in this integrative review were classified, grouped, and subsequently discussed according to the 
following criteria: year of publication, origin, indexation period, methodological approach, level and strength of evidence. 
The following was a summary of the main results of the studies, with the purpose of recommending or not the use of aspirin 
for primary prevention of CVD, considering benefits and risks, synthesis is presented in tables 1 and 2. 
Table 1 - Distribution of the selected studies, according to Title/Reference, Year/Country, Periodic, and Evidence/Strength. 
Search Data, 2014. 
Nº Title/Reference* Year/Country Periodic
Evidence/
Strength
01 Aspirin in the primary prevention of cardiovascular disease in the Women’s Health Study: effect of noncompliance12
2012
USA
Eur J Epidemiol
Level 2/
Strong
02 Utilização de ácido acetilsalicílico (AAS) na prevenção de doenças cardiovasculares: um estudo de base populacional04
2012
BRAZIL
Cad. Saúde 
Pública
Level 3/
Moderate
03 Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects13
2011
USA
European Heart 
Journal
Level 2/
Strong
04
Aspirin for the prevention of cardiovascular events in patients 
without clinical cardiovascular disease: a meta-analysis of 
randomized trials14
2011
USA
American Heart 
Journal
Level 1/
Strong
05
Aspirin for prevention of cardiovascular events in a general 
population screened for a low ankle brachial index: a randomized 
controlled trial15
2010
SCOTLAND
JAMA
Level 2/
Strong
06 Prevención primaria de la enfermedad cardiovascular con aspirina: ¿qué dicen las guías de práctica clínica?16
2010
SPAIN
Aten Primaria
Level 1/
Strong
07 Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials17
2009
USA
JAMA
Level 1/
Strong
Source: Authors
The first evidence was in relation to the year of publication of the studies. The prevalence of studies published between the 
years 2010 to 2012 (85.7%) was identified, with two studies published per year, and in 2009 there was only one publication 
(14.3%). This reveals the great and recent concern in the search for new ways of preventing CVD to those who have not yet 
been affected by them, taking more space in scientific publications.
In relation to the country of origin, four studies (57.1%) are of American origin (USA), one Spanish (14.3%), one 
Scottish (14.3%) and one Brazilian (14.3%). This shows that the use of aspirin for the prevention of CVD, whether primary 
or secondary, was only recently of interest to Brazilian publications. This is justified by the incentive to non-pharmacological 
measures to prevent such events, such as the National Policy for Health Promotion - ordinance 687/GM, March 30, 2006.18
In relation to the indexing journals, three were published in public health journals (European Journal Epidemiology, 
Atención Primaria and Caderno de Saúde Pública), two in medical journals (JAMA) and two health journals (American Heart 
Journal and European Heart Journal).
The studies were classified as to the type of methodology, in order to identify the use of quantitative and qualitative 
methods. Prevalence of quantitative studies (6 studies - 85.7%) is justified by the large number of controlled and randomized 
trials (3 studies), meta-analyzes (2 studies) and cross-sectional population studies (1 study), It is important to highlight the 
quantitative research for the identification and recommendation of the use of aspirin in the primary prevention of CVD, 
since these provide precision and reliability of the data for analysis. However, the importance of qualitative studies, due to 
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their subjectivity, and the ability to know deeply what is being investigated, is emphasized. In this study, we have a (14.3%) 
qualitative research of the systematic review type.
When considering the level of evidence and strength, the USA is highlighted again with four important works of strong 
evidence, being two level 1 of evidence, and two level 2 of evidence. When evaluating all this review with a great level of 
recommendation, therefore, it presents, besides the four American publications with a strong level of evidence, a level 1 
(Spain), a level 2 (Scotland) and a level 3 (Brazil), as can be observed in table 1, strong, strong and moderate , respectively.
Table 2 shows the methodological outlines and main conclusions of the selected studies in the integrative review. 
Table 2 - Presentation of the methodological outline and main conclusions of the selected studies. Research Data, 2014. 
Nº METHODOLOGICAL DESIGN / CONCLUSIONS
01
A randomized study of aspirin 100 mg taken on alternate days by women over 45 years without prior CVD. The 
analysis allowed us to conclude that the use of aspirin for primary prevention is effective in women as well as men; 
besides it is also effective in reducing mortality in patients with previous CVD, that is, in secondary prevention.
02
A cross-sectional population study with a sample of 2,710 individuals aged 45 years or older with at least 2 risk 
factors for CVD (Diabetes Mellitus - DM, Hypertension and/or dyslipidemia), who would need ASA for primary 
and/or secondary prevention. Prevalence of 24.8% and 34.3% of ASA use in primary and secondary prevention, 
respectively, is below the recommended level for CVD prevention.
03
Randomized and controlled study with 39,876 women aged 45 years or older, using aspirin 100 mg taken every 
other day. The study showed that aspirin use was ineffective and even harmful in the majority of the study 
population, as well as an association between individual characteristics and treatment.
04
Meta-analysis of 9 randomized trials that evaluated the effect of aspirin on primary prevention of major 
cardiovascular events. All the evidences investigated allow a modest recommendation of aspirin for the primary 
prevention of CVD due to its risks, such as severe hemorrhage.
05
A randomized controlled trial conducted between April 1988 and October 2008 with 28,980 men and women 
aged 50 to 75 years without prior CVD to evaluate the efficacy of 100 mg enteric coated aspirin. Comparing the 
aspirin and placebo / control groups, it was found to be significant the use of aspirin for the primary prevention 
of CVD, and not significant in secondary prevention and in reducing the risk of CVD mortality, and even though 
34 participants in the Aspirin group compared to 20 in the placebo group developed severe bleeding requiring 
hospital admission.
06
Systematic review of 14 guidelines for primary prevention of CVD (9) and for prevention in DM (5). It was 
evidenced that most of the guides recommend the use of aspirin for the primary prevention of CVD in diabetic 
patients, however, there are discrepancies between international centers and even in different documents of the 
same society.
07
Meta-analysis of 18 prospective and/or randomized studies of aspirin therapy involving 5,269 individuals with 
peripheral cardiovascular disease, with or without dipyridamole. Evidence has shown that the use of aspirin alone 
or in combination with dipyridamole for primary prevention of CVD is not significant, however, the use of non-fatal 
stroke reduction is significant. It also raised the need for randomized trials to evaluate the benefit / risk ratio of 
aspirin use for CVD prevention.
Source: Author
This study represents an attempt to build a consensus of the available evidence regarding the recommendations for 
primary prevention of CVD with the use of aspirin, providing a more careful and precise decision-making for care. CVD is 
a group of conditions that affect both the cardiovascular system and the blood vessels. They lead to a high rate of premature 
mortality in adults, and when not mortal, cause total or partial disability, reducing autonomy, and entailing repercussions not 
only for the individual, but also for the family and society.3 This is a major challenge for health policies.
There are complex, if not multivariable, factors in the genesis of CVD. Hence, Brazil’s investments, for example, in the 
creation of public health policies and programs, such as HiperDia, a program focused on clients with hypertension and/or 
diabetes.2 The focus of treatment is on prevention, changing habits and reducing risk factors, through dietary reeducation, 
exercise, smoking cessation, glycemic control, actions that can significantly reduce the incidence of CVD.4 However, today, 
we question the use of drugs with inhibitory action of platelet aggregation for the primary prevention of cardiovascular 
alterations, with aspirin being the object of our discussion.
Currently, some associations recommend the use of aspirin for primary prevention of CVD, such as the American 
Diabetes Association (ADA), which recommends the use of 75-162 mg of aspirin a day for the prevention of CVD in high-
risk diabetic patients, ie, men over 50 and women over 60 years old, with multiple risk factors, provided that they are at low 
risk of gastrointestinal bleeding and without contraindications to the use of ASA.4,16 This recommendation, to a certain extent, 
extends to the entire group of individuals at high risk of developing CVD. This is justified by the fact that there are no studies 
comparing different doses of aspirin, the dose of 100 mg/day being the most used in the studies.12,13,15
A large meta-analysis of 9 randomized trials evaluating the effect of aspirin on primary prevention of major cardiovascular 
events has shown that for every 1,000 patients treated for 5 years, there were 3 avoided cardiovascular events associated with 
3 major bleeding events, indicating that there was no net benefit, suggesting that strategies can be developed to maximize the 
benefits and minimize the risks.14 These results can be compared to a randomized clinical trial conducted with 28,980 men 
and women aged 50-75 years without prior CVD to evaluate the use of 100 mg aspirin for primary prevention, in which it 
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demonstrated 34 aspirin group participants compared to 
aspirin 20 from the placebo group who developed severe 
hemorrhage, requiring hospital admission.15
Thus, studies do not recommend the use of aspirin for 
the primary prevention of CVD when considering the most 
relevant risks when compared to the benefits. Among the 
risks, the studies mention: gastric mucosal lesion, upper 
gastrointestinal bleeding and gastrointestinal bleeding, also 
report that individuals undergoing anticoagulant therapy, 
recent gastrointestinal bleeding, liver disease, tendency to 
bleeding and allergy to aspirin are not candidates for this 
strategy (100 mg of aspirin daily).12-14,17
In this sense, knowing that nursing act as a member 
of the health team, has the most diverse ways of promoting 
health, such as home visit, nursing consultation, individual 
and/or collective educational process19, it is verified that it 
is essential for the nurse to know and take advantage of the 
recommendations, as well as the benefits and risks of the use of 
aspirin for the primary prevention of CVD, in order to provide 
the best care, providing an comprehensive patient care.
CONCLUSION
In clinical practice, the use of aspirin for primary 
prevention of CVD should therefore be weighed on a case-by-
case basis, meaning that patients at risk should be identified, 
using stratification tools adapted to the specific population.
These tools must be adapted, through rigorous studies to 
the population of a given geographical area, of the population of 
each country of origin. There is also a need for tools to assess the 
individual risk of bleeding, in order to know if, in fact, primary 
therapy will benefit with minimum risk. Another aspect to 
highlight is the optimal dose of aspirin. However, further studies 
and dose-specific adaptation to the target population are needed. 
In addition to a special training, the nursing team must be fit for 
a better follow-up and treatment for patients with CVD.
This research was limited because it included only articles 
in Portuguese, English and Spanish. The necessity of other 
randomized and controlled clinical trials that use the same 
intervention to evaluate such use is corroborated, because 
the studies included in this paper are very heterogeneous, not 
allowing the comparison between them. It is also concluded 
that, in addition to the reduced publications included in this 
review, the scientific production regarding pharmacological 
therapies for primary prevention of CVD is still incipient. 
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